Peter G Kerr

List of Publications by Year
in descending order

232 papers	12,800 citations	25034 57 h-index	28297 105 g-index
232 all docs	232 docs citations	232 times ranked	11878 citing authors

#	Article	IF	Citations
1	Mortality Risk for Dialysis Patients With Different Levels of Serum Calcium, Phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS). American Journal of Kidney Diseases, 2008, 52, 519-530.	1.9	888
2	Anemia management and outcomes from 12 countries in the dialysis outcomes and practice patterns study (DOPPS). American Journal of Kidney Diseases, 2004, 44, 94-111.	1.9	600
3	Prevalence of Kidney Damage in Australian Adults. Journal of the American Society of Nephrology: JASN, 2003, 14, S131-S138.	6.1	574
4	Vascular Access and All-Cause Mortality. Journal of the American Society of Nephrology: JASN, 2004, 15, 477-486.	6.1	384
5	Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney International, 2010, 77, 1098-1106.	5.2	357
6	Factors affecting outcomes in patients reaching end-stage kidney disease worldwide: differences in access to renal replacement therapy, modality use, and haemodialysis practices. Lancet, The, 2016, 388, 294-306.	13.7	295
7	High rates of death and hospitalization follow bone fracture among hemodialysis patients. Kidney International, 2014, 85, 166-173.	5.2	276
8	Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). American Journal of Kidney Diseases, 2004, 44, 34-38.	1.9	269
9	Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 96, 37-47.	5.2	235
10	Patient and Caregiver Priorities for Outcomes in Hemodialysis: An International Nominal Group Technique Study. American Journal of Kidney Diseases, 2016, 68, 444-454.	1.9	232
11	Developing a Set of Core Outcomes for Trials in Hemodialysis: An International Delphi Survey. American Journal of Kidney Diseases, 2017, 70, 464-475.	1.9	218
12	Associations between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease. Nephrology Dialysis Transplantation, 2007, 23, 586-593.	0.7	214
13	Cardiovascular Morbidity and Mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in Chronic Renal Failure. Journal of the American College of Cardiology, 2006, 47, 1108-1116.	2.8	208
14	Effects of Early and Late Intervention with Epoetin Î± on Left Ventricular Mass among Patients with Chronic Kidney Disease (Stage 3 or 4). Journal of the American Society of Nephrology: JASN, 2004, 15, 148-156.	6.1	206
15	Home Hemodialysis and Mortality Risk in Australian and New Zealand Populations. American Journal of Kidney Diseases, 2011, 58, 782-793.	1.9	168
16	The Directed Differentiation of Human iPS Cells into Kidney Podocytes. PLoS ONE, 2012, 7, e46453.	2.5	163
17	Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials. American Journal of Kidney Diseases, 2004, 43, 197-208.	1.9	161
18	Phosphate Binder Use and Mortality Among Hemodialysis Patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): Evaluation of Possible Confounding by Nutritional Status. American Journal of Kidney Diseases, 2012, 60, 90-101.	1.9	159

#	Article	IF	Citations
19	Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney International, 2002, 62, 2167-2175.	5.2	157
20	Longer dialysis session length is associated with better intermediate outcomes and survival among patients on in-center three times per week hemodialysis: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrology Dialysis Transplantation, 2012, 27, 4180-4188.	0.7	144
21	Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). American Journal of Kidney Diseases, 2004, 44, 34-38.	1.9	133
22	Status of care for end stage kidney disease in countries and regions worldwide: international cross sectional survey. BMJ: British Medical Journal, 2019, 367, l5873.	2.3	131
23	Transition from pediatric to adult renal services: a consensus statement by the International Society of Nephrology (ISN) and the International Pediatric Nephrology Association (IPNA). Pediatric Nephrology, 2011, 26, 1753-1757.	1.7	127
24	Renal participation of myeloperoxidase in antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis. Kidney International, 2015, 88, 1030-1046.	5.2	127
25	Associations of hemodialysis dose and session length with mortality risk in Australian and New Zealand patients. Kidney International, 2006, 69, 1229-1236.	5.2	124
26	Blood pressure levels and mortality risk among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney International, 2012, 82, 570-580.	5.2	120
27	Bisphosphonates in Chronic Kidney Disease; Balancing Potential Benefits and Adverse Effects on Bone and Soft Tissue. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 221-233.	4.5	117
28	Transition from pediatric to adult renal services: a consensus statement by the International Society of Nephrology (ISN) and the International Pediatric Nephrology Association (IPNA). Kidney International, 2011, 80, 704-707.	5.2	112
29	Time and exercise improve phosphate removal in hemodialysis patients. American Journal of Kidney Diseases, 2004, 43, 85-89.	1.9	110
30	Attenuation of aortic calcification with lanthanum carbonate versus calciumâ€based phosphate binders in haemodialysis: A pilot randomized controlled trial. Nephrology, 2011, 16, 290-298.	1.6	109
31	Calcium kinetics and the long-term effects of lowering dialysate calcium concentration. Kidney International, 1993, 43, 630-640.	5.2	108
32	Association of Carotid Intima-Medial Thickness and Indices of Arterial Stiffness With Cardiovascular Disease Outcomes in CKD. American Journal of Kidney Diseases, 2007, 50, 622-630.	1.9	108
33	Effect of Alendronate on Vascular Calcification in CKD Stages 3 and 4: A Pilot Randomized Controlled Trial. American Journal of Kidney Diseases, 2010, 56, 57-68.	1.9	99
34	Arterial function after successful renal transplantation. Kidney International, 2004, 65, 1882-1889.	5.2	95
35	Allogeneic Mesenchymal Precursor Cells (MPC) in Diabetic Nephropathy: A Randomized, Placebo-controlled, Dose Escalation Study. EBioMedicine, 2016, 12, 263-269.	6.1	95
36	Renal dialysis abatement: lessons from a social study. Palliative Medicine, 2005, 19, 389-396.	3.1	91

#	Article	IF	Citations
37	Generation of Induced Pluripotent Stem Cells from Human Kidney Mesangial Cells. Journal of the American Society of Nephrology: JASN, 2011, 22, 1213-1220.	6.1	83
38	Prospective Psychosocial Monitoring of Living Kidney Donors Using the Short Form-36 Health Survey: Results at 12 Months. Transplantation, 2004, 78, 1384-1389.	1.0	82
39	Global access of patients with kidney disease to health technologies and medications: findings from the Global Kidney Health Atlas project. Kidney International Supplements, 2018, 8, 64-73.	14.2	82
40	Histopathologic and Clinical Predictors of Kidney Outcomes inÂANCA-Associated Vasculitis. American Journal of Kidney Diseases, 2014, 63, 227-235.	1.9	80
41	Impact of intradialytic exercise on arterial compliance and Bâ€type natriuretic peptide levels in hemodialysis patients. Hemodialysis International, 2008, 12, 254-263.	0.9	79
42	Health-related quality of life in Australian adults with renal insufficiency: A population-based study. American Journal of Kidney Diseases, 2003, 41, 596-604.	1.9	78
43	Effect of Fish Oil Supplementation and Aspirin Use on Arteriovenous Fistula Failure in Patients Requiring Hemodialysis. JAMA Internal Medicine, 2017, 177, 184.	5.1	77
44	Does monthly native arteriovenous fistula blood-flow surveillance detect significant stenosisâ€”a randomized controlled trial. Nephrology Dialysis Transplantation, 2006, 21, 2498-2506.	0.7	74
45	Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrology Dialysis Transplantation, 2010, 25, 4009-4017.	0.7	73
46	Research Priorities in CKD: Report of a National Workshop Conducted in Australia. American Journal of Kidney Diseases, 2015, 66, 212-222.	1.9	73
47	Vascular calcification and arterial stiffness in chronic kidney disease: Implications and management. Nephrology, 2007, 12, 500-509.	1.6	71
48	Effect of a Vascular Access Nurse Coordinator to Reduce Central Venous Catheter Use in Incident Hemodialysis Patients: A Quality Improvement Report. American Journal of Kidney Diseases, 2009, 53, 99-106.	1.9	71
49	Clinical impact of genomic testing in patients with suspected monogenic kidney disease. Genetics in Medicine, 2021, 23, 183-191.	2.4	70
50	mTOR-mediated podocyte hypertrophy regulates glomerular integrity in mice and humans. JCI Insight, 2019, 4, .	5.0	69
51	Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrology Dialysis Transplantation, 2008, 23, 3654-3661.	0.7	68
52	A Single Low-Fixed Dose of Rituximab to Salvage Renal Transplants From Refractory Antibody-Mediated Rejection. Transplantation, 2009, 87, 286-289.	1.0	68
53	Standardised outcomes in nephrology â€“ Haemodialysis (SONG-HD): study protocol for establishing a core outcome set in haemodialysis. Trials, 2015, 16, 364.	1.6	67
54	Identifying Outcomes Important to Patients with Glomerular Disease and Their Caregivers. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 673-684.	4.5	66

#	Article	IF	Citations
55	ESRD in Australia and New Zealand at the end of the millennium: A report from the ANZDATA registry. American Journal of Kidney Diseases, 2002, 40, 1122-1131.	1.9	63
56	How Australian nephrologists view home dialysis: Results of a national survey. Nephrology, 2011, 16, 446-452.	1.6	62
57	Peritoneal Dialysis Use and Practice Patterns: An International Survey Study. American Journal of Kidney Diseases, 2021, 77, 315-325.	1.9	62
58	Podocyte Number in Children and Adults. Journal of the American Society of Nephrology: JASN, 2015, 26, 2277-2288.	6.1	61
59	Review of dialysate calcium concentration in hemodialysis. Hemodialysis International, 2006, 10, 326-337.	0.9	60
60	Mycophenolate and lower graft function reduce the seroresponse of kidney transplant recipients to pandemic H1N1 vaccination. Kidney International, 2012, 82, 212-219.	5.2	60
61	Failure of a daily haemofiltration programme using a highly permeable membrane to return Î²2-microglobulin concentrations to normal in haemodialysis patients. Nephrology Dialysis Transplantation, 1992, 7, 924-930.	0.7	58
62	DEOXYSPERGUALIN SUPPRESSES LOCAL MACROPHAGE PROLIFERATION IN RAT RENAL ALLOGRAFT REJECTION. Transplantation, 1994, 58, 596-601.	1.0	58
63	Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology, 2009, 10, 1.	1.8	58
64	Precise quantification of dialysis using continuous sampling of spent dialysate and total dialysate volume measurement. Kidney International, 1997, 52, 530-537.	5.2	56
65	Cells surrounding haemodialysis-associated amyloid deposits are mainly macrophages. Nephrology Dialysis Transplantation, 1994, 9, 662-667.	0.7	55
66	Human podocyte depletion in association with older age and hypertension. American Journal of Physiology - Renal Physiology, 2016, 310, F656-F668.	2.7	55
67	Conservative Management and End-of-Life Care in an Australian Cohort with ESRD. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 2195-2203.	4.5	54
68	Outcomes of Extended-Hours Hemodialysis Performed Predominantly at Home. American Journal of Kidney Diseases, 2013, 61, 247-253.	1.9	52
69	A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD). Journal of the American Society of Nephrology: JASN, 2020, 31, 2653-2666.	6.1	52
70	The association between patient activation and selfâ€€care practices: A crossâ€€sectional study of an Australian population with comorbid diabetes and chronic kidney disease. Health Expectations, 2017, 20, 1375-1384.	2.6	51
71	Effectiveness of self-management support interventions for people with comorbid diabetes and chronic kidney disease: a systematic review and meta-analysis. Systematic Reviews, 2018, 7, 84.	5.3	51
72	Treatment for lupus nephritis. , 2004, , CD002922.		50

#	Article	IF	Citations
73	Thalassemia Bone Disease: A 19-Year Longitudinal Analysis. Journal of Bone and Mineral Research, 2014, 29, 2468-2473.	2.8	50
74	Kt/V in CAPD by different estimations of V. Kidney International, 1995, 48, 563-569.	5.2	47
75	Longitudinal Body Composition Changes Due to Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1668-1675.	4.5	47
76	The fragility of significant results underscores the need of larger randomized controlled trials in nephrology. Kidney International, 2017, 92, 1469-1475.	5.2	47
77	An Interview Study of Patient and Caregiver Perspectives on Advance Care Planning in ESRD. American Journal of Kidney Diseases, 2018, 71, 216-224.	1.9	46
78	Serum 25-Hydroxyvitamin D Deficiency and the 5-Year Incidence of CKD. American Journal of Kidney Diseases, 2013, 62, 58-66.	1.9	45
79	Assessment of the Nutritional State of Dialysis Patients. Blood Purification, 1996, 14, 382-387.	1.8	43
80	of Intermittent v Continuous Therapy. American Journal of Kidney Diseases, 1988, 12, 304-306.	1.9	42
81	Intensive Hemodialysis and Mortality Risk in Australian andÂNewÂZealand Populations. American Journal of Kidney Diseases, 2016, 67, 617-628.	1.9	42
82	Prospective Quality-of-Life Monitoring of Simultaneous Pancreas and Kidney Transplant Recipients Using the 36-Item Short Form Health Survey. American Journal of Kidney Diseases, 2010, 55, 698-707.	1.9	41
83	Temporal Changes in Mortality Risk by Dialysis Modality in the Australian and New Zealand Dialysis Population. American Journal of Kidney Diseases, 2015, 66, 489-498.	1.9	41
84	Global overview of health systems oversight and financing for kidney care. Kidney International Supplements, 2018, 8, 41-51.	14.2	41
85	Outcome of a screening program for vancomycinâ€resistant enterococci in a hospital in Victoria. Medical Journal of Australia, 1999, 171, 133-136.	1.7	40
86	Prospective psychosocial monitoring of living kidney donors using the SF-36 health survey. Transplantation, 2003, 76, 807-809.	1.0	40
87	Seasonal modifications in blood pressure are mainly related to interdialytic body weight gain in dialysis patients. Kidney International, 2004, 65, 1795-1801.	5.2	40
88	Review: Membranes for haemodialysis. Nephrology, 2010, 15, 381-385.	1.6	40
89	The Perspectives of Patients on Health-Care for Co-Morbid Diabetes and Chronic Kidney Disease: A Qualitative Study. PLoS ONE, 2016, 11, e0146615.	2.5	40
90	Carotid Artery Intima-Medial Thickness Is Increased In Chronic Renal Failure. Clinical and Experimental Pharmacology and Physiology, 2000, 27, 639-641.	1.9	39

#	Article	IF	Citations
91	Improving CKD-MBD management in haemodialysis patients: barrier analysis for implementing better practice. Nephrology Dialysis Transplantation, 2011, 26, 1319-1326.	0.7	39
92	Scope and Consistency of Outcomes Reported in Randomized Trials Conducted in Adults Receiving Hemodialysis: A Systematic Review. American Journal of Kidney Diseases, 2018, 72, 62-74.	1.9	39
93	Smad4 promotes diabetic nephropathy by modulating glycolysis and <scp>OXPHOS</scp>. EMBO Reports, 2020, 21, e48781.	4.5	39
94	Determination and Validation of Aortic Calcification Measurement from Lateral Bone Densitometry in Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 119-127.	4.5	38
95	Factors associated with patient activation in an Australian population with comorbid diabetes and chronic kidney disease: a cross-sectional study. BMJ Open, 2017, 7, e017695.	1.9	38
96	Factors associated with foot ulceration and amputation in adults on dialysis: a cross-sectional observational study. BMC Nephrology, 2017, 18, 293.	1.8	38
97	Atherosclerosis and folic acid supplementation trial in chronic renal failure: Baseline results. Nephrology, 2004, 9, 130-141.	1.6	37
98	Waterâ€soluble vitamin levels in extended hours hemodialysis. Hemodialysis International, 2011, 15, 30-38.	0.9	37
99	Zygomycosis requiring amputation of the hand: an isolated case in a patient receiving haemodialysis. Medical Journal of Australia, 1988, 148, 258-259.	1.7	35
100	Relationship between vascular calcification, arterial stiffness and bone mineral density in a crossâ€sectional study of prevalent Australian haemodialysis patients. Nephrology, 2009, 14, 105-112.	1.6	35
101	Karyomegalic nephropathy: an uncommon cause of progressive renal failure. Nephrology Dialysis Transplantation, 2002, 17, 1914-1920.	0.7	34
102	25-hydroxyvitamin D Levels and chronic kidney disease in the AusDiab (Australian Diabetes, Obesity and) Tj ETQq0 0 0 rgBT /Overlock 10	1.8	33
103	Predictors of Health-Related Quality of Life in Patients with Co-Morbid Diabetes and Chronic Kidney Disease. PLoS ONE, 2016, 11, e0168491.	2.5	33
104	Whole Blood Serotonin Levels Are Markedly Elevated in Patients on Dialytic Therapy. American Journal of Nephrology, 1992, 12, 14-18.	3.1	32
105	Haemolysis in haemodialysis. Nephrology, 2017, 22, 838-847.	1.6	28
106	Attitudes and Practices of Australian Nephrologists Toward Implementation of Clinical Genomics. Kidney International Reports, 2021, 6, 272-283.	0.8	28
107	Native arteriovenous fistula blood flow and resistance during hemodialysis. American Journal of Kidney Diseases, 2003, 41, 132-139.	1.9	27
108	Epidemiology of vascular access in the Australian hemodialysis population. Kidney International, 2003, 64, 1893-1902.	5.2	27

#	Article	IF	Citations
109	Reduction in Î²2-Microglobulin With Super-flux Versus High-flux Dialysis Membranes: Results of a 6-Week, Randomized, Double-blind, Crossover Trial. American Journal of Kidney Diseases, 2008, 52, 93-101.	1.9	27
110	The Effects of Reprocessing High-Flux Polysulfone Dialyzers With Peroxyacetic Acid on Î²2-Microglobulin Removal in Hemodiafiltration. American Journal of Kidney Diseases, 1992, 19, 433-438.	1.9	26
111	Preeclampsia and Long-term Renal Function in Women Who Underwent Kidney Transplantation. Obstetrics and Gynecology, 2018, 131, 57-62.	2.4	26
112	Lateral lumbar Xâ€ray assessment of abdominal aortic calcification in Australian haemodialysis patients. Nephrology, 2011, 16, 389-395.	1.6	25
113	Deferasirox at therapeutic doses is associated with dose-dependent hypercalciuria. Bone, 2016, 85, 55-58.	2.9	25
114	Defining the relationship between average glucose and HbA1c in patients with type 2 diabetes and chronic kidney disease. Diabetes Research and Clinical Practice, 2014, 104, 84-91.	2.8	24
115	Self-management in patients with diabetes and chronic kidney disease is associated with incremental benefit in HRQOL. Journal of Diabetes and Its Complications, 2017, 31, 427-432.	2.3	24
116	Hemodialysis Use and Practice Patterns: An International Survey Study. American Journal of Kidney Diseases, 2021, 77, 326-335.e1.	1.9	24
117	THE EFFECTS OF OKT3 THERAPY ON INFILTRATING LYMPHOCYTES IN REJECTING RENAL ALLOGRAFTS. Transplantation, 1989, 48, 33-36.	1.0	23
118	Vascular access practice patterns in the New Zealand hemodialysis population. American Journal of Kidney Diseases, 2004, 43, 696-704.	1.9	23
119	Glomerular hypertrophy in subjects with low nephron number: contributions of sex, body size and race. Nephrology Dialysis Transplantation, 2014, 29, 1686-1695.	0.7	23
120	Increased incidence of benign breast disease in female renal transplant patients receiving cyclosporin. ANZ Journal of Surgery, 2002, 72, 222-225.	0.7	22
121	The Impact of Standard High-Flux Polysulfone Versus Novel High-Flux Polysulfone Dialysis Membranes on Inflammatory Markers: A Randomized, Single-Blinded, Controlled Clinical Trial. American Journal of Kidney Diseases, 2007, 49, 533-539.	1.9	22
122	Home haemodialysis in Australia â€" is the wheel turning full circle?. Medical Journal of Australia, 2010, 192, 403-406.	1.7	22
123	Reduction in Protein-Bound Solutes Unacceptable as Marker of Dialysis Efficacy during Alternate-Night Nocturnal Hemodialysis. American Journal of Nephrology, 2011, 34, 226-232.	3.1	22
124	The ultrafiltration coefficient of a dialyser (KUF) is not a fixed value, and it follows a parabolic function: the new concept of KUF max. Nephrology Dialysis Transplantation, 2011, 26, 636-640.	0.7	22
125	ARTERIAL CALCIFICATION AND STIFFNESS IN CHRONIC KIDNEY DISEASE. Clinical and Experimental Pharmacology and Physiology, 2007, 34, 683-687.	1.9	21
126	Home hemodialysis in Australia: Current perspective. Hemodialysis International, 2008, 12, S6-S10.	0.9	21

#	Article	IF	Citations
127	Home Hemodialysis in Australia and New Zealand: How and Why it has been Successful. Seminars in Dialysis, 2011, 24, 658-663.	1.3	21
128	A case of hypophosphatemic osteomalacia secondary to deferasirox therapy. Journal of Bone and Mineral Research, 2012, 27, 219-222.	2.8	21
129	The Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post-initiation trial modifications. BMC Nephrology, 2015, 16, 89.	1.8	21
130	Are traditional risk factors valid for assessing cardiovascular risk in endâ€stage renal failure patients?. Nephrology, 2008, 13, 667-671.	1.6	20
131	Increasing home based dialysis therapies to tackle dialysis burden around the world: A position statement on dialysis economics from the 2nd Congress of the International Society for Hemodialysis. Nephrology, 2011, 16, 53-56.	1.6	20
132	Standardised Outcomes in Nephrologyâ€”Polycystic Kidney Disease (SONG-PKD): study protocol for establishing a core outcome set in polycystic kidney disease. Trials, 2017, 18, 560.	1.6	20
133	Aortic vascular calcification is inversely associated with the trabecular bone score in patients receiving dialysis. Bone, 2018, 113, 118-123.	2.9	20
134	Identifying patientâ€important outcomes in polycystic kidney disease: An international nominal group technique study. Nephrology, 2019, 24, 1214-1224.	1.6	20
135	Cardiovascular risk in dialysis patients: A comparison of risk factors and cardioprotective therapy between 1996 and 2001. Nephrology, 2003, 8, 177-183.	1.6	19
136	Cinacalcet reduces plasma intact parathyroid hormone, serum phosphate and calcium levels in patients with secondary hyperparathyroidism irrespective of its severity. Clinical Nephrology, 2011, 76, 233-243.	0.7	19
137	Water quality in conventional and home haemodialysis. Nature Reviews Nephrology, 2012, 8, 725-734.	9.6	19
138	Renal genetics in Australia: Kidney medicine in the genomic age. Nephrology, 2019, 24, 279-286.	1.6	18
139	<scp>KHAâ€CARI</scp> guideline: Dialysis adequacy (haemodialysis): Dialysis membranes. Nephrology, 2013, 18, 485-488.	1.6	17
140	Primary and tertiary health professionalsâ€™ views on the health-care of patients with co-morbid diabetes and chronic kidney disease â€“ a qualitative study. BMC Nephrology, 2016, 17, 50.	1.8	17
141	Reliability and validity of the coping strategy inventory-short form applied to hemodialysis patients in 13 countries: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Journal of Psychosomatic Research, 2016, 91, 12-19.	2.6	17
142	Dialyzer Performance in the Clinic: Comparison of Six Lowâ€Fluxâ€ƒMembranes. Artificial Organs, 1999, 23, 817-821.	1.9	16
143	A Rational Guide to Reducing Fracture Risk in Dialysis Patients. Seminars in Dialysis, 2010, 23, 43-54.	1.3	16
144	Kidney transplant recipient perspectives on telehealth during the COVIDâ€19 pandemic. Transplant International, 2021, 34, 1517-1529.	1.6	16

#	Article	IF	Citations
145	Prevalence and treatment of cardiovascular disease and traditional risk factors in Australian adults with renal insufficiency. Nephrology, 2005, 10, 40-47.	1.6	15
146	Thrice-weekly nocturnal hemodialysis: the overlooked alternative to improve patient outcomes. Nephrology Dialysis Transplantation, 2013, 28, 2447-2455.	0.7	15
147	Cost-Effectiveness of Targeted Exome Analysis as a Diagnostic Test in Glomerular Diseases. Kidney International Reports, 2021, 6, 2850-2861.	0.8	15
148	Determinants of native arteriovenous fistula blood flow. Nephrology, 2004, 9, 205-211.	1.6	14
149	Measurement of vascular calcification using CT fistulograms. Nephrology Dialysis Transplantation, 2006, 22, 484-490.	0.7	14
150	Models of care for coâ€morbid diabetes and chronic kidney disease. Nephrology, 2018, 23, 711-717.	1.6	14
151	Endothelial Progenitor Cells and Vascular Health inÂDialysis Patients. Kidney International Reports, 2018, 3, 205-211.	0.8	14
152	Maintenance of elevated versus physiological iron indices in non-anaemic patients with chronic kidney disease: a randomized controlled trial. Nephrology Dialysis Transplantation, 2010, 25, 920-926.	0.7	13
153	Effect of exercise on albuminuria in people with diabetes. Nephrology, 2011, 16, 704-709.	1.6	13
154	Alternate Night Nocturnal Hemodialysis: The Australian Experience. Seminars in Dialysis, 2011, 24, 664-667.	1.3	13
155	Human mesenchymal stem cells alter the gene profile of monocytes from patients with Type 2 diabetes and end-stage renal disease. Regenerative Medicine, 2016, 11, 145-158.	1.7	13
156	Serum phosphorus levels and fracture following renal transplantation. Clinical Endocrinology, 2017, 87, 141-148.	2.4	13
157	The Adequacy of Fragmin as a Single Bolus Dose with Reused Dialyzers. Artificial Organs, 1994, 18, 416-419.	1.9	12
158	Renal anaemia: Recent developments, innovative approaches and future directions for improved management (Review Article). Nephrology, 2006, 11, 542-548.	1.6	12
159	Using vertebral bone densitometry to determine aortic calcification in patients with chronic kidney disease. Nephrology, 2010, 15, 575-583.	1.6	12
160	Historical controlled trial of OKT3 versus basiliximab induction therapy in simultaneous pancreas-renal transplantation. Nephrology, 2003, 8, 212-216.	1.6	11
161	Randomized, placebo-controlled trial of intramuscular vitamin B12for the treatment of hyperhomocysteinaemia in dialysis patients. Internal Medicine Journal, 2003, 33, 489-494.	0.8	11
162	Increasing homeâ€based dialysis therapies to tackle dialysis burden around the world: A position statement on dialysis economics from the 2nd Congress of the International Society for Hemodialysis. Hemodialysis International, 2011, 15, 10-14.	0.9	11

#	Article	IF	Citations
163	Blood Pressure and Blood Volume: Acute and Chronic Considerations in Hemodialysis. Seminars in Dialysis, 2013, 26, 62-72.	1.3	11
164	The stability and variability of serum and plasma fibroblast growth factor-23 levels in a haemodialysis cohort. BMC Nephrology, 2018, 19, 325.	1.8	11
165	The impact of an integrated diabetes and kidney service on patients, primary and specialist health professionals in Australia: A qualitative study. PLoS ONE, 2019, 14, e0219685.	2.5	11
166	Risk factors for foot ulceration in adults with end-stage renal disease on dialysis: a prospective observational cohort study. BMC Nephrology, 2019, 20, 423.	1.8	11
167	Health-related quality of life among patients with comorbid diabetes and kidney disease attending a codesigned integrated model of care: a longitudinal study. BMJ Open Diabetes Research and Care, 2020, 8, e000842.	2.8	11
168	The impact of glycaemic control on outcomes in patients with end-stage renal disease and type 2 diabetes (Review Article). Nephrology, 2008, 13, 124-127.	1.6	10
169	International Differences in Hemodialysis Delivery and Their Influence on Outcomes. American Journal of Kidney Diseases, 2011, 58, 461-470.	1.9	10
170	A pilot study of an influenza vaccination or mask mandate in an Australian tertiary health service. Medical Journal of Australia, 2014, 200, 83-84.	1.7	10
171	Baseline characteristics of the omegaâ€3 fatty acids (<scp>F</scp>ish oils) and <scp>A</scp>spirin in <scp>V</scp>ascular access <scp>OU</scp>tcomes in <scp>RE</scp>nal <scp>D</scp>isease (<scp>FAVOURED</scp>) study. Nephrology, 2016, 21, 217-228.	1.6	10
172	Urolithiasis is prevalent and associated with reduced bone mineral density in Î²â€thalassaemia major. Internal Medicine Journal, 2017, 47, 1064-1067.	0.8	10
173	PHENOTYPIC DEFINITION OF PRIMED T CELLS IN HUMAN RENAL ALLOGRAFTS. Transplantation, 1989, 48, 787-789.	1.0	9
174	Focal segmental glomerulosclerosis and Guillainâ€“Barre syndrome associated with Campylobacter enteritis. Internal Medicine Journal, 2007, 37, 724-728.	0.8	9
175	Increasing home dialysis knowledge through a webâ€based eâ€learning program. Nephrology, 2014, 19, 345-351.	1.6	9
176	Isolated proteinuria due to CUBN homozygous mutation â€“ challenging the investigative paradigm. BMC Nephrology, 2019, 20, 330.	1.8	9
177	Patient-reported barriers and outcomes associated with poor glycaemic and blood pressure control in co-morbid diabetes and chronic kidney disease. Journal of Diabetes and Its Complications, 2019, 33, 63-68.	2.3	9
178	Availability, coverage, and scope of health information systems for kidney care across world countries and regions. Nephrology Dialysis Transplantation, 2021, 37, 159-167.	0.7	9
179	Anti-CD20 antibody treatment in refractory Class IV lupus nephritis. Nephrology Dialysis Transplantation, 2006, 22, 291-293.	0.7	8
180	Body composition in home haemodialysis versus conventional haemodialysis: a cross-sectional, matched, comparative study. Nephrology Dialysis Transplantation, 2010, 25, 568-573.	0.7	8

#	Article	IF	Citations
181	Different faces of <scp>N</scp>ocardia infection in renal transplant recipients. Nephrology, 2016, 21, 254-260.	1.6	8
182	Home Hemodialysis: What Is Old Is New Again. Contributions To Nephrology, 2017, 190, 146-155.	1.1	8
183	Fish oil and aspirin effects on arteriovenous fistula function: Secondary outcomes of the randomised omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) trial. PLoS ONE, 2019, 14, e0213274.	2.5	8
184	A need-based approach to self-management education for adults with co-morbid diabetes and chronic kidney disease. BMC Nephrology, 2019, 20, 113.	1.8	8
185	Predictors of Arteriovenous Fistula Failure: A Post Hoc Analysis of the FAVOURED Study. Kidney360, 2020, 1, 1259-1269.	2.1	8
186	Dialyzer Reuse: Interaction Between Dialyzer Membrane, Disinfectant (Formalin), and Blood During Dialyzer Reprocessing. Artificial Organs, 1996, 20, 53-55.	1.9	7
187	Renal allograft re-use and herpetic re-infection. Nephrology, 2015, 20, 17-21.	1.6	7
188	<scp>DEBATE</scp>: Should Dialysis at Home be Mandatory for All Suitable <scp>ESRD</scp> Patients?. Seminars in Dialysis, 2015, 28, 147-154.	1.3	7
189	Use of deferasirox (Exjade) for iron overload in peritoneal dialysis patients. Nephrology, 2018, 23, 887-889.	1.6	7
190	Nephrology in the Oceaniaâ€“South East Asia region: perspectives and challenges. Kidney International, 2018, 94, 465-470.	5.2	7
191	The Use of Live Cell Imaging and Automated Image Analysis to Assist With Determining Optimal Parameters for Angiogenic Assay in vitro. Frontiers in Cell and Developmental Biology, 2019, 7, 45.	3.7	7
192	Relationship between measured and prescribed dialysate sodium in haemodialysis: a systematic review and meta-analysis. Nephrology Dialysis Transplantation, 2021, 36, 695-703.	0.7	7
193	Vancomycin-resistant enterococci colonization does not increase mortality in end-stage kidney failure: a caseâ€“control study. Journal of Hospital Infection, 2013, 85, 289-296.	2.9	6
194	The effect of holiday haemodialysis treatments on patient mood, adverse symptoms and subjective wellbeing using the Big Red Kidney Bus. Nephrology, 2017, 22, 107-113.	1.6	6
195	Low versus high dialysate calcium concentration in alternate night nocturnal hemodialysis: A randomized controlled trial. Hemodialysis International, 2017, 21, 19-28.	0.9	6
196	Is there a role for plasma exchange in rapidly progressive glomerulonephritis?. Nephrology, 2001, 6, 141-143.	1.6	5
197	Patient reported barriers are associated with low physical and mental well-being in patients with co-morbid diabetes and chronic kidney disease. Health and Quality of Life Outcomes, 2018, 16, 215.	2.4	5
198	Vitamin D therapy in chronic kidney disease: back to the future?. Clinical Nephrology, 2015, 84 (2015), 65-74.	0.7	5

#	Article	IF	Citations
199	Bilateral Periureteric Junction Obstruction Causing Renal Failure in Two Elderly Patients. American Journal of Nephrology, 1989, 9, 47-50.	3.1	4
200	Advanced chronic kidney disease, cardiovascular events and the effect of diabetes: data from the Atherosclerosis and Folic Acid Supplementation Trial. Internal Medicine Journal, 2011, 41, 825-832.	0.8	4
201	Keeping Home Dialysis Patients at Home. American Journal of Kidney Diseases, 2016, 67, 542-544.	1.9	4
202	Preventing Intradialytic Hypotension: Translating Evidence into Practice. Nephrology Nursing Journal, 2017, 44, 131-151.	0.2	4
203	HEMODYNAMIC AND PLASMA RENIN RESPONSES TO TREATMENT OF A RENAL ARTERIOVENOUS MALFORMATION. Australian and New Zealand Journal of Medicine, 1986, 16, 1-4.	0.5	3
204	Predicting vascular access failure: A collective review. Nephrology, 2002, 7, 170-176.	1.6	3
205	How much is enough? An investigation of the relationship between haemodialysis adequacy and quality of life of elderly patients. Nephrology, 2016, 21, 314-320.	1.6	3
206	Updates on baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology, 2017, 22, 823-824.	1.6	3
207	Biochemical comparison of 8 h haemodialysis and 4 h haemodiafiltration, and two dialysis membranes, in a randomized crossâ€over trial. Nephrology, 2019, 24, 542-549.	1.6	3
208	Control of postâ€transplant erythrocytosis by enalapril. Medical Journal of Australia, 1994, 161, 544-546.	1.7	3
209	A pilot study comparing the efficiency of a novel asymmetric cellulose triacetate (<scp>ATA</scp>) dialyser membrane (<scp>Solaceaâ€190H</scp>) to a standard high flux polysulfone dialyser membrane (<scp>FX</scp>â€80) in the setting of extended hours haemodialysis. Nephrology, 2022, 27, 494-500.	1.6	3
210	Comparison of dialysis adequacy at two dialysate potassium concentrations. Nephrology, 2001, 6, 89-91.	1.6	2
211	Nocturnal hemodialysisâ€”should we still provide this therapy?. Nature Reviews Nephrology, 2011, 7, 611-612.	9.6	2
212	Placental Pathology in Pregnancies After Kidney Transplantation. Transplantation, 2020, 104, e214-e215.	1.0	2
213	Home and facility haemodialysis patients: a comparison of outcomes in a matched cohort. Nephrology Dialysis Transplantation, 2021, 36, 1070-1077.	0.7	2
214	A Novel Approach to Enhance the Regenerative Potential of Circulating Endothelial Progenitor Cells in Patients with End-Stage Kidney Disease. Biomedicines, 2022, 10, 883.	3.2	2
215	A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial. Journal of Vascular Access, 2024, 25, 193-202.	0.9	2
216	Recent trends in haemodialysis: Australia 1994. Nephrology, 1995, 1, 3-10.	1.6	1

#	Article	IF	Citations
217	Dialysis in Australia and New Zealand. , 2012, , 611-619.		1
218	The Authors Reply. Kidney International, 2014, 86, 649.	5.2	1
219	What are the Causes of the Ill Effects of Chronic Hemodialysis?. Seminars in Dialysis, 2014, 27, 18-21.	1.3	1
220	Home based therapies: can wishes be realized?. Nephrology Dialysis Transplantation, 2020, 35, 1836-1839.	0.7	1
221	A co-designed integrated kidney and diabetes model of care improves mortality, glycaemic control and self-care. Nephrology Dialysis Transplantation, 2022, 37, 1472-1481.	0.7	1
222	Response to COVID-19 Infection in Hemodialysis Patients: An Australian Perspective. Kidney360, 2020, 1, 829-833.	2.1	1
223	Taking a broader view of the health care needs of people with chronic kidney disease. Medical Journal of Australia, 2022, 216, 137-138.	1.7	1
224	CKDâ€"Where Have All the Women Gone?. Kidney International Reports, 2022, 7, 375-377.	0.8	1
225	Evaluation of an in-line dialysate urea monitor including assessment of 'V'. Nephrology, 1996, 2, 195-198.	1.6	0
226	Phosphate removal in haemodialysis: Effect of two different dialysis membranes. Nephrology, 1996, 2, 405-407.	1.6	0
227	High-flux dialysers*. Nephrology, 2002, 7, 33-36.	1.6	0
228	Evaluation of fistula blood flow and resistance by regression analysis: in reply. American Journal of Kidney Diseases, 2003, 42, 614a-615.	1.9	0
229	The impact of the Christmas holiday effect on interdialytic weight gain in hemodialysis patients: A multicenter observational retrospective cohort study. Hemodialysis International, 2021, 25, 257-264.	0.9	0
230	Nephrology in Australia. , 2021, , 701-721.		0
231	Hypercalcemia, Hypocalcemia, and Hypomagnesemia. , 2009, , 81-87.		0
232	Dietary habits in Australian, New Zealand and Malaysian patients with end stage kidney failure: A preâ€specified crossâ€sectional study of the FAVOURED trial participants. Journal of Human Nutrition and Dietetics, 2022, 35, 1178-1191.	2.5	0